conditions. The practice is compounded by the relative lack of available pharmacotherapeutic options for those failing to respond to first-line treatments. Evidence-based medicine requires that we raise the questions of (i) whether there is any good evidence for efficacy of SGAs for non-psychotic indications; and (ii) the evidence regarding risk.
Mood and anxiety disorders are consistently found to be the most prevalent psychiatric disorders 1 2 and are among the most burdensome of all medical conditions. 3 Treatment is open-label data that a particular compound in this class is likely to be superior to its 'classmates', the commercial incentive for support is lost to the pharmaceutical industry.
The last reason is likely to account for the general lack of research on augmentation strategies in refractory psychiatric conditions. This is likely to be compounded by the knowledge that the compounds are already being widely used for many off-label indications.
For the range of disorders for which SGAs have been tested in psychiatry, 5, 6 less than 10% of studies are double-blind and randomised. 
